Company: Hana Biosciences
Starting stock price: $5.94
Ending stock price: $1.06
Percent Change: -82.15%
Details: Hana Biosciences is a South San Francisco company focused on cancer treatments. It has two compounds in clinical trials and others in preclinical development. In August 2007, its its Marqibo product was fast-tracked by the FDA for use in leukemia patients suffering their second relapse. In October, it announced $30 million in financing from Deerfield Management.
Hana gains $30M credit line to back discovery work. Report
Hana gains orphan drug status. Report
FDA to review Hana nausea therapy. Report